Myelosuppression by sunitinib is flt-3 genotype dependent
Open Access
- 3 August 2010
- journal article
- letter
- Published by Springer Nature in British Journal of Cancer
- Vol. 103 (5) , 757-758
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitorsBritish Journal of Cancer, 2009
- Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced ToxicityJournal of Clinical Oncology, 2009
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side EffectsCurrent Drug Metabolism, 2009
- Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell CarcinomaEuropean Urology, 2008
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 2006